Oruka Therapeutics ORKA 深 沪
等待开盘 09-16 09:30:00 美东时间
92.20
-3.730
-3.89%
华盛通- 最 高95.805
- 今 开95.14
- 成交量 78.47万股
- 最 低 90.41
- 昨 收 95.93
- 总市值 61.05亿
- 52周最高 115.515
- 市盈率 静 --
- 换手率 1.19%
- 52周最低 15.77
- 委 比 83.26%
- 总股本 6620.97万
- 历史最高 5922.804
- 量 比 1.19
- 振 幅 5.62%
- 历史最低 -0.636
- 每 手 1
- 风险率 27.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
Oruka Therapeutics, a clinical-stage biotech company developing novel biologics for chronic skin diseases like plaque psoriasis and hidradenitis suppurativa, announced its participation in the 2026 Morgan Stanley Global Healthcare Conference in New York from September 14-16. The company aims to provide patients with high rates of disease clearance through infrequent dosing, potentially as little as once or twice a year.
09-09 20:01
Oruka Therapeutics Appoints Todd Edwards Chief Commercial Officer
Oruka Therapeutics ( ($ORKA) ) has issued an announcement. On July 22, 2026, Or...
08-25 05:07
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
Oruka Therapeutics appoints Todd Edwards as Chief Commercial Officer. With over 25 years of experience in immunology and dermatology, Edwards joins from Arcutis where he led successful commercial transformations. Oruka aims to advance its biologics for chronic skin diseases like plaque psoriasis and hidradenitis suppurativa. Edwards' leadership is expected to strengthen the company's commercial capabilities.
08-24 20:01
Oruka Therapeutics Files Prospectus For Offering $1B Mixed Shelf
https://www.sec.gov/Archives/edgar/data/907654/000121390026092612/ea0301041-s3_oruka.htm
08-22 04:21
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.
08-11 22:28
Oruka Therapeutics Q2 EPS $(0.55) Misses $(0.51) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.51) by 7.84 percent. This is a 19.57 percent decrease over losses of $(0.46) per share from the same period last year.
08-10 19:19
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
08-03 18:21
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
